Evidence map›Paper›PMID 39897068›Full record

ArticleSovremennye tekhnologii v meditsine2024

Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.

O A Shashkova, L A Terekhina, I S Malakhov, A A Pinevich, N L Vartanyan, K O Avrov, I Yu Krutetskaya, I V Gryazeva, M A Berlina, A Yu Stolbovaya and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

O A ShashkovaPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
L A TerekhinaResearcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
I S MalakhovSenior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia; Postgraduate Student, Institute of Virology and Cell Biology; University of Lübeck, 160 Ratzeburger Allee, Lübeck, 23562, Germany.
A A PinevichPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia; Senior Lecturer, Cytology and Histology Department, Biological Faculty; Saint Petersburg State University, 7/9 Universitetskaya Naberezhnaya, Saint Petersburg, 199034, Russia.
N L VartanyanPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
K O AvrovPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
I Yu KrutetskayaPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
I V GryazevaPhD, Senior Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
M A BerlinaLaboratory Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
A Yu StolbovayaResearcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
I V SmirnovPhD, Leading Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
S V FedorenkoEngineer of the 1 Category, Physical and Technical Support Group of Radiation Therapy; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
A A KrylovaLaboratory Researcher, Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
M A NadporojskiiResearcher, Department of Cyclotron-Produced Radiopharmaceuticals; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
S V ShatikPhD, Head of the Department of Cyclotron-Produced Radiopharmaceuticals; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
A A StanzhevskiiDSc, Deputy Director of Research; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
M P SamoilovichDSc, Chief Researcher, Head of the Hybridoma Technology Laboratory; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia; Chief Researcher, Cytology and Histology Department, Biological Faculty; Saint Petersburg State University, 7/9 Universitetskaya Naberezhnaya, Saint Petersburg, 199034, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Materials and Methods: Genetically modified cells expressing human PD-L1 (strain CT26-PD-L1) were obtained by retroviral transduction of murine CT26 carcinoma cells. Results: CT26-PD-L1 strain of murine tumor cells expressing human membrane PD-L1 was created. When transplanted into intact BALB/c mice or sublethally irradiated F1(DBA×BALB/c) mice, these cells formed tumors. Thus, a significant advantage of the model was the possibility of Conclusion: The created cells are the first genetically engineered cells designed to evaluate affinity of anti-human PD-L1 therapeutic and diagnostic agents in Russia. Test results confirmed the model suitability for

Indexed as

B7-H1 AntigenImmunoconjugatesAnimalsCell Line, TumorGallium RadioisotopesHumansLutetiumMiceMice, Inbred BALB CRadioisotopesSingle-Domain AntibodiesB7-H1 AntigenCD274 protein, humanGallium RadioisotopesImmunoconjugatesLutetiumLutetium-177RadioisotopesSingle-Domain Antibodiescell modelCT26PD-L1radioconjugatetargeted agenttumor modelVHH

Identifiers

PMID39897068
PMCPMC11784882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.